Previous 10 | Next 10 |
MacroGenics (MGNX) and Zai Lab (ZLAB) have entered into an exclusive collaboration and license agreement involving up to four immuno-oncology molecules.MacroGenics provides rights to Zai Lab for its DART and TRIDENT multi-specific platforms and a lead research program targeting solid tumors. ...
Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific molecules MacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific platforms and a lead research program targeting solid tumors ...
The following slide deck was published by Zai Lab Limited in conjunction with this event. For further details see: Zai Lab Limited (ZLAB) Investor Presentation - Slideshow
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good wa...
Shanghai's Zai Lab in-licensed Greater China rights to adagrasib, a KRASG12C inhibitor, from Mirati of San Diego in a $338 million agreement. Stemirna Therapeutics raised nearly $200 million to finance clinical trials and production of its messenger RNA COVID-19 vaccine candidate. ...
Mirati Therapeutics (MRTX) and Zai Lab (ZLAB) have entered into a collaboration and license agreement for adagrasib, a small-molecule KRASG12C inhibitor, in Greater China (mainland China, Hong Kong, Macau and Taiwan).Mirati will receive a $65M upfront p...
Zai Lab obtains the right to develop and exclusively commercialize adagrasib in mainland China, Hong Kong, Macau and Taiwan Mirati to receive an upfront payment of $65 million, up to approximately $273 million in potential milestone payments and high-teen- to low-twenties-percent ...
Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China - Zai Lab obtains the right to develop and exclusively commercialize adagrasib in China, Hong Kong, Macau and Taiwan - Mirati to receive an upfront payment of $...
Zai Lab (ZLAB) announces dosing of the first patient in China in the registrational Phase 2 portion of TRIDENT-1 study of repotrectinib in certain patients with non-small cell lung cancer ((NSCLC)).The study, being conducted by its partner Turning Point Therapeutics and Zai Lab...
TRIDENT-1 study is enrolling patients with ROS1+ advanced NSCLC and NTRK+ advanced solid tumors. SHANGHAI and SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company today announced do...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...